Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Baricitinib in Systemic Sclerosis: a Phase IV, Double-blinded, Controlled Study.

NCT05300932 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT05300932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05300932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Baricitinib in Systemic Sclerosis: a Phase IV, Double-blinded, Controlled Study.
Lead sponsor
Tongji Hospital
Phase
Phase 4
Overall status
Active, not recruiting
Start date
March 8, 2022
Completion date
November 12, 2026
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis